Giant wins ArgiNox account

Share this article:

ArgiNox Pharmaceuticals, of Menlo Park, Ca named Giant Creative Strategy as the agency of record for their lead compound, tilarginine acetate. Tilarginine acetate is currently being studied in clinical trials for the treatment of cardiogenic shock. Giant will work with ArgiNox to develop an integrated scientific market preparation campaign, as well as naming and all branding and promotional materials for the product's impending launch.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?